Ginsenoside Rh1 mitigates mitochondrial dysfunction induced by myocardial ischaemia through its novel role as a sirtuin 3 activator
Rh1 is a novel SIRT3 activator and protects against myocardial ischaemia-induced mitochondrial dysfunction, providing new clues to prevent and treat ischaemic injury-associated CVD.
Authors
- Junping Kou (ORCID: https://orcid.org/0000-0001-8377-915X)
- Boyang Yu (ORCID: https://orcid.org/0000-0001-6135-947X)
- Shuhua Fang (ORCID: https://orcid.org/0000-0002-6709-9784)
- Jingui Hu
- Yue Li (ORCID: https://orcid.org/0000-0001-9505-4009)
- Fang Li (ORCID: https://orcid.org/0000-0002-7617-6534)
- Hong Chen (ORCID: https://orcid.org/0000-0003-3042-0324)
- Mengyu Li (ORCID: https://orcid.org/0000-0002-3122-650X)
- Shuaishuai Gong (ORCID: https://orcid.org/0000-0002-4563-0204)
Institutions
- China Pharmaceutical University (CN)
- Lishui City People's Hospital (CN)
- Nanjing Jiangning Hospital (CN)
- Southeast University (CN)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1111/bph.70022
- Citations
- 15
- Primary Topic
- Sirtuins and Resveratrol in Medicine
- Type
- article
- Field-Weighted Citation Impact
- 18.36
Funders
- National Natural Science Foundation of China
- Qinglan Project of Jiangsu Province of China
- Fundamental Research Funds for the Central Universities